All In MedTech

Device Trial Radar · NCT00582036

Glucose Control In Hematopoetic Stem Cell Transplant

Last checked: Nov 20, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

11

Actual

Start

Feb 2007

Primary completion

May 2009

Study completion May 2009

Sponsor

Lead sponsor
University of OklahomaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Oklahoma Center for the Advancement of Science and Technology
First posted
Dec 28, 2007

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine whether intensive glucose control results in improved mortality and reduced hospital stay length by performing a randomized trial of intensive glucose management (blood glucose goal 110 mg/dl) using continuous IV insulin and glucose vs. non-intensive glucose management (goal 200 mg/dl)

Conditions

  • Hyperglycemia
  • Hematopoietic Stem Cell Transplantation

Interventions

  • Regular InsulinDrug

    Use of sliding scale insulin as per Appendix 1

  • Deployment of the MiniMed Paradigm monitoring deviceDevice

    Automated insulin delivery system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intensive Control of Glucose Effects on Mortality in Allogenic Hematopoietic Stem Cell Transplant (HSCT)Time frame: 100 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.